Investigators also want to combine ipilimumab with drugs that attack the tumour directly.
研究者也设想将ipilimumab和直接进攻肿瘤的药物结合使用。
These two researchers have been running a full-scale clinical trial of ipilimumab, an antibody that stimulates patients' immune systems to kill tumours.
他们对单克隆抗体ipilimumab进行了全面的临床研究,ipilimumab是刺激患者免疫系统进而杀灭癌症细胞的一种抗体。
Almost a quarter of those treated with ipilimumab were alive two years after treatment started. That compared with 14% of those treated just with the vaccine.
几乎四分之一的使用了ipilimumab治疗的患者自从开始治疗活了2年的时间,而相比之下只使用疫苗治疗的患者只有14%的人活那么长。
应用推荐